A Phase 3 interventional study of TAK-875 and TAK-875 in Diabetes Mellitus, sponsored by Takeda. Completed at 19 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-11-09.
Sponsored by Takeda · Phase 3 and Interventional
The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.
11,090 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 192 is above the median of 80 across 8,491 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Takeda is the lead sponsor of 1,025 studies on the registry; 91 are open to participants now.
Of its 177 completed or terminated interventional studies of FDA-regulated products, 153 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
HbA1c
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TAK-875